The neurokinin-3 receptor (NK~3~R) is a class A GPCR with neurokinin B (NKB) as its endogenous agonist. We present here the sequel on the lead optimization of *N*-acyl-triazolopiperazine NK~3~R antagonists (**1** and **2**, Figure [1](#fig1){ref-type="fig"}).^[@ref1]^

![Lead progression: iv POC (**1**), oral POC (**2**), and clinical candidate (**3**). (The "magic methyl" groups are shown in red.)](ml-2015-00117d_0002){#fig1}

NK~3~R antagonists were speculated as therapeutically relevant for CNS dysfunctions, e.g., schizophrenia, predicated on the "hyperdopaminergic hypothesis", which repeatedly met with clinical failures in over a decade of efforts.^[@ref2]^ Meanwhile, emerging biology has unambiguously established the role of NK~3~R/NKB signaling in reproductive neuroendocrinology. Importantly, recent studies have revealed NK~3~R as a key regulatory component of the hypothalamic--pituitary--gonadal (HPG) axis wherein its tonic activation positively regulates the gonadotropin-releasing hormone (GnRH) pulse frequency.^[@ref3]^ In turn, the GnRH pulse frequency is known to differentially control the circulating levels of luteinizing hormone (LH) versus follicle-stimulating hormone (FSH). Thus, high frequency pulses stimulate LH release, whereas low frequency pulses favor FSH induction.^[@ref4]^ These gonadotropins ultimately act on the ovary and testis to promote production of gametes and sex-hormone release. In 2011, it was reported that patients with a loss of function mutation in NK~3~R display a phenotype of normosomic congenital hypogonadotropic hypogonadism, low plasma LH, and attendant low LH/FSH ratios that could be restored through exogenous administration of GnRH.^[@ref5]^ We have demonstrated elsewhere^[@ref6]^ that the foregoing NK~3~R antagonists slow the LH pulse and decrease circulating LH levels without affecting FSH, consistent with the literature reports.^[@ref4]^ As such, these antagonists are subtle modulators of gonadotropin secretion unlike GnRH ligands that abrogate both LH and FSH with the consequent decline in plasma estrogen to castration levels thereby triggering menopausal-like adverse events such as bone mineral density loss and incidences of hot flashes.^[@ref7]^ Hence, NK~3~R antagonists offer a potentially safer therapeutic approach due to a decreased rather than abrogated GnRH pulse frequency. Collectively, these findings offer a strong rationale for repositioning NK~3~R antagonists to address sex-hormones disorders such as polycystic ovary syndrome (PCOS) and uterine fibroids (UF), among others.^[@ref8]^

The synthetic approach to the analogues herein was previously described.^[@ref1]^ With minor modifications, Scheme [1](#sch1){ref-type="scheme"} was used for the GMP scale-up of **3** in overall 42% yield (2.7 kg) with 99.3% purity and \>99.9% enantiomeric excess.

![Reagents and conditions: (a) Et~3~OBF~4~, Na~2~CO~3~, CH~2~Cl~2~, 45 min, 68%; (b) MeOH, 70 °C, 8 h, 80%; (c) TFA, 2 h, \>99% conversion; (d) 4-fluorobenzoyl chloride, NaHCO~3~, 15 min, 97%; (e) recrystallization (EtOH/H~2~O), 97% (DMB = 2,4-dimethoxybenzyl).](ml-2015-00117d_0004){#sch1}

The in vitro bioactivity structure--activity relationship (SAR) was established through radioligand binding (p*K*~i~) and aequorin functional assays (pIC~50~) data from recombinant human NK~3~R in CHO cells. The lead optimization strategy^[@ref1]^ of combined improvement in both bioactivity and ligand lipophilic efficiency (LLE = p*K*~i~ -- log*D*~7.4~)^[@ref9]^ was maintained. An initial emphasis was placed on LLE as a predictive marker of improved safety profiles.^[@ref10]^ Other efficiency metrics such as LE^[@ref11]^ and Fsp^3^ ^[@ref12]^ (Table [1](#tbl1){ref-type="other"}) were also tracked, though not as a primary focus. The previously discovered "magic methyl" groups in Rings B and D (Figure [1](#fig1){ref-type="fig"}),^[@ref1]^ so-called due to their significant impact in improving potency *and* LLE, remained crucial and rendered feasible improvements in Fsp^3^ and LE as well (see below).

To recall, replacing 2-methylthiazole (**2**) at Ring D with 3-methyl-1,2,4-thiadiazole (**8**) was reported earlier to markedly improve bioactivity and LLE (Table [1](#tbl1){ref-type="other"}).^[@ref1]^ Moreover, 1,2,4-thiadiazole is regarded as a means of circumventing bioactivation liabilities potentially relevant to the thiazole ring.^[@ref13]^ These considerations overall prompted us to retain the 1,2,4-thiadiazole, but to modify the 4-(thiophen-2-yl)phenyl in **8** to the 4-fluorophenyl Ring A (i.e., **3**) present in the earlier lead structures.^[@ref1]^ Progression from **8** to **3** helped reduce lipophilicity (Δlog*D*~7.4~ = −1.5), which not surprisingly right-shifted bioactivity by nearly one log. However, in evaluating **3** against **8**, the improved LLE and absence of the thiophene ring (a potential structural safety alert)^[@ref14]^ was considered of greater importance due to the reduced toxicological risk. In addition, **3** was nearly equipotent to the oral POC lead **2**, while \>1-log superior in LLE. Narrowing our focus on the thiadiazole Ring D and related variants, we observed the following descending trend in bioactivity (Table [1](#tbl1){ref-type="other"}): 1,2,4-thiadiazole (**3**) \> 1,2,4-oxadiazole (**10**) ≫ 1,3,4-thiadiazole (**9**). As with the Ring A cases, increased lipophilicity in Ring D helped improve bioactivity albeit offset by a loss in LLE, e.g., **11** vs **10** (Table [1](#tbl1){ref-type="other"}). The impact of Rings B and D magic methyl groups on SAR trends was quite pronounced, as expected based on previous results,^[@ref1]^ since the corresponding *des*-Me analogues of **3**, whether at Ring B or D (**12** and **13**, respectively), were decidedly inferior in both bioactivity and LLE (Table [1](#tbl1){ref-type="other"}). *Gem* dimethyl Ring B substitution substantially eroded the bioactivity (**14** vs **3**) in keeping with the unfavorable impact of (*S*)-Me at this Ring B position (data not shown).^[@ref1]^ Once again, improved bioactivity followed increased lipophilicity whether at Ring A (**15**) or at Ring D (**16**) positions, but this gain was negated by a deteriorated LLE against **3**. Conversely, replacing 4-fluorophenyl with phenyl at Ring A, i.e., **17**, helped diminish lipophilicity, but it also deteriorated bioactivity. Interestingly, a hydroxyethyl substitution at Ring B (**18**) afforded an alternative means of reducing lipophilicity (Δlog*D*~7.4~ = −0.5 vs **3**) with minimal impact on bioactivity, thus resulting in a 0.4-log superior LLE vs **3**. Despite this, **18** proved inferior to **3** due to P~gp~ efflux that in turn markedly diminished its brain exposure level (Table [2](#tbl2){ref-type="other"} and discussion further below).

The hERG SAR herein (Table [1](#tbl1){ref-type="other"}) was governed by the interplay between lipophilicity and the hydrogen-bond acceptor (HBA) count in the heteroaryl Ring D, as previously reported.^[@ref1]^ For instance, in progressing from **8** to **3** (Δlog*D*~7.4~ = 1.5), the hERG IC~50~ was improved by over 12-fold. However, the poor hERG IC~50~ = 1.6 μM in **11** (log*D*~7.4~ = 1.7) was in keeping with the increased HBA count in the Ring D oxadiazole (N + N + O) in stark contrast to the thiadiazole (N + N) Ring D variations (**3** and **15**--**18**), all of which displayed a superior hERG, IC~50~ ≥ 39 μM (log*D*~7.4~ = 1.3--2.4). Interestingly, the Ring B hydroxyl group in **18** did not adversely impact hERG (IC~50~ = 50 μM) suggesting that the HBA effect on hERG SAR is primarily a Ring D related effect. Finally, the Ring B magic methyl also reduced hERG efficacy, i.e., **3** (IC~50~ \> 100 μM) vs **12** (IC~50~ = 50 μM). Compound **3** was the best overall in the hERG and CYP safety profile evaluation.

Based on the free drug hypothesis, the unbound fraction rather than total drug is relevant for PKPD analysis.^[@ref15]^ The NK~3~R is mainly expressed on KNDy neurons in the ARC region of the hypothalamus^[@ref3]^ that is part of the circumventricular organs lacking blood--brain barrier and are therefore exposed to blood solutes.^[@ref16]^ As such, both the unbound plasma (*f*~u~) and the unbound brain levels (bf~u~) must be considered here (Table [2](#tbl2){ref-type="other"}). While lipophilicity alone does not correlate well to albumin binding, this trend is often apparent in a congeneric series.^[@ref17]^ Hence, a compound with balanced lipophilicity such as **3** (log*D*~7.4~ = 1.5) displayed high *f*~u~ and bf~u~ levels (\>50%) in contrast to the more lipophilic congeners, e.g., **16** (Table [2](#tbl2){ref-type="other"}). It is noteworthy that despite an increase in unbound plasma concentration, the systemic clearance levels (CL~T~) remained low (e.g., **3**, Table [2](#tbl2){ref-type="other"}). The comparatively lower CL~T~ in para substituted phenyl Ring A (**3**, **15**) against the unsubstituted congener **17** is likely due to the metabolic blocking effect. All analogues except **18** displayed high Caco-2 permeability with no evidence of appreciable P~gp~ efflux (ER = 0.6--1.2), consistent with the high oral availability (%*F*) and brain-to-plasma ratios observed. The so-called P~gp~ rule-of-4 suggests that increasing the number of HBA atoms to (N + O) ≥ 8 tends to confer an increasing likelihood of P~gp~ efflux.^[@ref18]^ This is in keeping with the P~gp~ efflux in **18** (ER = 3.8) given its HBA atom count (N + O = 8). As with **2**,^[@ref1]^ a complete oral absorption (%*F* \> 100) was also observed in rat with compound **12** and in monkey with **3**. This phenomenon is well-known and various underlying causes have been reported.^[@ref19]^ No drug accumulation was observed in 5-day once-daily oral dosing studies in rats (**3** and **12**) or monkeys (**3**), despite administration of elevated doses (e.g., up to 1 g/kg in rats with **12**), in step with the relatively short half-life values and the previous related observations with **2**.^[@ref1]^ Moreover, no adverse hepatotoxicity (AST, ALT, and bilirubin levels normal) was detected in these subchronic studies. Furthermore, **3** displayed the highest bf~u~ = 0.525 and brain unbound concentration (*C*~brain,u~ = 343 nM) herein (Table [2](#tbl2){ref-type="other"}). In contrast, **18** although nearly completely unbound in the brain displayed a comparatively low *C*~brain,u~ = 45.6 nM consistent with its elevated P~gp~ efflux ratio.

###### Human NK~3~R In Vitro Bioactivity, Log*D*~7.4~, Ligand Efficiency Metrics,^[@ref10]−[@ref12]^ and Off-Target Safety SAR

![](ml-2015-00117d_0005){#gr100}

*N* = 3, %RSD ≤ 5.

CYP 3A4, 2D6, 2C9, 2C19, and 1A2, respectively (*N* = 2, \<10% variability).

*N* = 3, coefficient of variation \< 6%.

The key PKPD parameters for interpreting the LH inhibition data are the unbound plasma and brain levels normalized with respect to the bioactivity, i.e., *C*~plasma,u~/*K*~i~ and *C*~brain u~/*K*~i~ (Table [3](#tbl3){ref-type="other"}).^[@ref1]^ The plasma and brain levels were determined at the *T*~max~ for the minimum effective dose (MED). As noted before for **2** and **8**,^[@ref1]^ a statistically significant effect was attained at *C*~plasma,u~/*K*~i~ ≥ 7.6 and *C*~brain,u~/*K*~i~ \> 1 in rat oral LH inhibition studies. This was also the case here, i.e., for analogues **3**, **12**, and **16**--**18**, with MED values ranging from 3 mg/kg (**3**) to 30 mg/kg (**12** and **17**). For example, in rats, **3** was 20-fold more efficacious in vivo against the initial POC lead **2** despite being 3-fold right-shifted in *K*~i~. This ameliorated efficacy is reflected in their respective MED-normalized plasma and brain PKPD parameters (Table [3](#tbl3){ref-type="other"}, the last two columns). Otherwise stated, the \>1-log LLE superiority of **3** vs **2** underscores the greater unbound exposure levels and consequently the greater in vivo efficacy of **3**. Likewise, the monkey LH data (Figure [2](#fig2){ref-type="fig"}) mirrored these trends with **3** 4-fold more efficacious (MED levels) although nearly equipotent to **2** in monkey *K*~i~ values (Table [3](#tbl3){ref-type="other"}) in keeping with the significantly better MED-normalized plasma PKPD parameter for **3** vs **2**.

![Oral LH inhibition with **3** (0.5% MC/water) in castrated cynomolgus monkey (2-way ANOVA and Dunnet's comparison to the vehicle; \*\*\**p* \< 0.001, \*\**p* \< 0.01).](ml-2015-00117d_0003){#fig2}

In summary, **3** proved a superior lead candidate based on bioactivity, LLE, LE, and Fsp^3^ (Table [1](#tbl1){ref-type="other"}) criteria. Apart from its excellent hERG and CYP safety profile, **3** was highly efficacious in LH inhibition, showed \>2.5-log selectivity against NK~1~R and NK~2~R subtypes, proved \>300-fold selective against related HPG axis receptors^[@ref1]^ (KOR, GnRH, GnIH-R, GPR54), and was highly selective in the broad CEREP off-target screen (\<25% inhib at 10 μM). Finally, **3** showed no effect either in Langendorff cardiac safety in rabbits (up to 30 μM) or in AMES genotoxicity test (up to 100 μM). Compound **3** (ESN364) is currently in phase 2 clinical trials for the treatment of PCOS and UF.

###### Permeability, Plasma and Brain Fraction Unbound, Brain Exposure, and PK Data[a](#t2fn1){ref-type="table-fn"}

                                           Caco-2 *P*~app~ (nm/sec)                                                                                   
  ---------------------------------------- -------------------------- ----- ----- -------- ------- ------- ------- ------ ------ ------ ------ ------ ------
  **2**[b](#t2fn2){ref-type="table-fn"}    339                        224   0.7   rat      0.055   0.028   54.4    7.79   0.14   7.4    1.4    126    119
  **2**[c](#t2fn3){ref-type="table-fn"}    −                          −     −     monkey   0.043   −       17.9    −      −      16.5   1.52   210    12
  **3**[b](#t2fn2){ref-type="table-fn"}    487                        465   1.0   rat      0.639   0.525   1507    343    0.23   1.5    0.60   279    62.5
  **3**[c](#t2fn3){ref-type="table-fn"}    −                          −     −     monkey   0.532   −       5040    −      −      3.17   1.15   324    107
  **8**[d](#t2fn4){ref-type="table-fn"}    360                        221   0.6   rat      0.065   0.031   58.6    39.3   0.67   7.3    2.8    267    −
  **12**[d](#t2fn4){ref-type="table-fn"}   477                        528   1.1   rat      0.674   0.436   1767    212    0.12   1.94   0.65   239    126
  **15**[d](#t2fn4){ref-type="table-fn"}   467                        345   0.7   rat      0.408   −       −       −      −      2.2    0.91   294    73.6
  **16**[d](#t2fn4){ref-type="table-fn"}   419                        368   0.9   rat      0.291   0.109   348.0   85.4   0.25   1.07   2.25   1479   98.2
  **17**[d](#t2fn4){ref-type="table-fn"}   437                        519   1.2   rat      0.592   0.604   406.7   68.6   0.17   13.7   0.68   35     55
  **18**[d](#t2fn4){ref-type="table-fn"}   91                         345   3.8   rat      0.662   0.995   897.4   45.6   0.05   5.07   1.59   215    46.6

PK doses: iv, 1 mg/kg (rat), 10 mg/kg (monkey); oral, 3 mg/kg (rat), 5 mg/kg (monkey). Brain exposure dose: 1 mg/kg. Mean values for *N* = 3--4 rats, or 4 monkeys, per group. All rat data at 60 min: (B/P)~u~ = *C*~brain,u~/*C*~plasma, u~ with *C*~brain,u~ = *C*~brain, total~ × bf~u~ and *C*~plasma,u~ = *C*~plasma,total~ × *f*~u~. Monkey *C*~plasma,u~ data at 90 min (oral).

PK formulation: HPβCD.

PK formulation: iv HPβCD; oral 0.5% MC/water.

PK formulation: 1% DMSO, HPβCD in 0.9% NaCl.

###### PKPD Analysis of the Oral LH Inhibition Studies[a](#t3fn1){ref-type="table-fn"}

  Cpd   species   *K*~i~ (nM)   LLE   MED (mg/kg)   *T*~max~ (min)   *C*~plasma,u~/*K*~i~   *C*~brain,u~/*K*~i~   (*C*~plasma,u~/*K*~i~)/MED   (*C*~brain,u~/*K*~i~)/MED
  ----- --------- ------------- ----- ------------- ---------------- ---------------------- --------------------- ---------------------------- ---------------------------
  2     rat       76            4.0   60            150              16.4                   2.32                  0.273                        0.039
  2     monkey    20            4.6   20            60               13.3                   −                     0.665                        −
  3     rat       219           5.2   3             150              22.0                   5.03                  7.33                         1.68
  3     monkey    25            6.1   5             90               192                    −                     38.4                         −
  8     rat       22            4.6   10            150              15.0                   12.4                  1.5                          1.24
  12    rat       2033          4.5   30            150              22.5                   2.77                  0.75                         0.09
  16    rat       85            4.7   10            150              23.8                   5.87                  2.38                         0.59
  17    rat       573           4.9   30            45               47.3                   7.71                  1.58                         0.26
  18    rat       244           5.6   10            45               38.9                   1.82                  3.89                         0.18

Plasma concentrations coincident with LH measurements. MED determined by a significant decrease (*p* \< 0.05) in LH vs baseline with a lower nonsignificant dose established in all cases.

Experimental details for the synthesis and characterization of compounds, X-ray structure of **3** (accession code: CCDC 1052911), and pharmacology and profiling assays. The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsmedchemlett.5b00117](http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.5b00117).
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bf~u~
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(B/P)~u~
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CYP

:   cytochrome P-450

FSH

:   follicle-stimulating hormone

Fsp^3^
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HBA

:   hydrogen-bond acceptor
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HPβCD

:   9% hydroxypropyl-β-cyclodextrin
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:   hypothalamic--pituitary--gonadal
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:   kisspeptin-neurokinin B-dynorphin A neuron
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:   luteinizing hormone

LE

:   ligand efficiency

LLE
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:   minimum effective dose
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:   neurokinin B

NK~3~R

:   neurokinin-3 receptor

P~gp~

:   P-glycoprotein

PKPD

:   pharmacokinetic--pharmacodynamic

POC

:   proof-of-concept

*T*~1/2~

:   elimination half-life

*V*~ss~

:   steady-state volume of distribution
